11/14/2025

Aachen, Germany, 14 November 2025 – Grünenthal, a science-based pharmaceutical company and a leader in pain management, today announced the extension of its existing issue of Senior Secured Notes due 2031 (the “Existing Notes”) by €175 million (the “Additional Notes”) to a total sum of €675 million. The Additional Notes are expected to be issued and settled on 26 November 2025 (the “Issue Date”).

9/4/2025

Aachen, Germany, 4 September 2025 – Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery systems.

6/2/2025

Aachen, Germany, 2 June 2025 – Grünenthal today announced the acquisition of the commercial rights to Cialis^® (tadalafil) in Mexico, Brazil and Colombia from Eli Lilly and Company. Over the next few years, Grünenthal and Lilly will work together to transfer the manufacturing to Grünenthal's production site in Santiago, Chile, that will supply Cialis^® for Mexico, Brazil and Colombia moving forward.

5/20/2025

Aachen, Germany, 20th May 2025 – Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has played a key role in evolving the company’s Communications department since 2021.

3/27/2025

Aachen, Germany, 27 March 2025 – Grünenthal, a global leader in pain management and research, has published its 2024 financial results, marking a year of impressive resilience, strategic growth and operational excellence.

2/24/2025

Aachen, Germany & Toronto, Canada, 24 February 2025 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza^®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.

1/9/2025

Aachen, Germany, 09 January 2025 – Grünenthal announced today that Prof. Dr. Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025.